Outset Medical Files 8-K on Financial Condition, Reg FD Disclosure

Ticker: OM · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1484612

Outset Medical, INC. 8-K Filing Summary
FieldDetail
CompanyOutset Medical, INC. (OM)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-disclosure

TL;DR

**Outset Medical just dropped an 8-K about financial results and Reg FD, get ready for potential stock movement.**

AI Summary

Outset Medical, Inc. filed an 8-K on January 8, 2024, to report on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure.' This filing indicates that the company is providing an update on its financial performance and other material non-public information, likely in preparation for an earnings call or investor presentation. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock price (OM) depending on whether the results exceed or fall short of expectations.

Why It Matters

This filing signals that Outset Medical is about to release or has just released important financial updates, which could significantly influence investor sentiment and the stock's performance.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying financial disclosure it points to carries inherent market risk depending on the nature of the results.

Analyst Insight

A smart investor would monitor Outset Medical's (OM) news releases and investor relations pages for the specific financial results and disclosures referenced in this 8-K, as these will provide the actual substance impacting the company's valuation.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What specific items are being reported in this 8-K filing by Outset Medical, Inc.?

Outset Medical, Inc. is reporting under 'ITEM INFORMATION: Results of Operations and Financial Condition' and 'ITEM INFORMATION: Regulation FD Disclosure' as of January 8, 2024.

What is the trading symbol and the exchange where Outset Medical, Inc.'s common stock is registered?

The trading symbol for Outset Medical, Inc.'s Common Stock is OM, and it is registered on The Nasdaq Stock Market LLC.

What is the business address and phone number of Outset Medical, Inc. as stated in the filing?

Outset Medical, Inc.'s business address is 3052 Orchard Dr., San Jose, California 95134, and its telephone number is (669) 231-8200.

What is the state of incorporation for Outset Medical, Inc.?

Outset Medical, Inc. is incorporated in Delaware.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024.

Filing Stats: 991 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2024-01-08 08:40:29

Key Financial Figures

Filing Documents

02 Result of Operations and Financial Condition

Item 2.02 Result of Operations and Financial Condition. On January 8, 2024, Outset Medical, Inc. (the “Company”) issued a press release announcing, among other items, expected revenue for the fourth quarter and fiscal year ended December 31, 2023, as well as guidance for 2024 revenue and non-GAAP gross margin. A copy of the Company’s press release is furnished herewith as Exhibit 99.1. Certain financial information contained in Exhibit 99.1 is preliminary, unaudited and subject to change or adjustment in connection with the completion of the Company’s quarter and year-end closing processes and the preparation of its audited financial statements for the fiscal quarter and year ended December 31, 2023, which will be contained in the Company’s related Annual Report on Form 10-K.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 8, 2024, the Company posted a presentation on the investor section of its website at investors.outsetmedical.com to be used by the Company in connection with its participation in the J.P. Morgan Healthcare Conference. A copy of the presentation is furnished herewith as Exhibit 99.2. The information contained in Items 2.02 and 7.01 (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements This report and the exhibits attached hereto contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements include, but are not limited to, statements about the Company’s unaudited results of operations, including fourth quarter and full year 2023 revenue, statements about possible or assumed future results of operations and financial position, including expectations regarding projected revenues and non-GAAP gross margin, profitability and outlook; statements regarding the Company’s overall business strategy, plans and objectives of management; the Company’s expectations regarding the market sizes and growth potential for Tablo and the total addressable market opportunities for Tablo, the Company's planned expansion within the home hemodialysis market, and continued execution of the Company's initiatives designed go expand gross margins; as well as the Company’s expectations regarding the impact of macroeconomic factors on the Company, its customers and suppliers. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission, including its latest annual

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release entitled “Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance” dated January 8, 2024 99.2 Investor Presentation dated January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Outset Medical, Inc. Date: January 8, 2024 By: /s/Nabeel Ahmed Nabeel Ahmed Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing